Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives

Marco Gallo, Pasqualino Malandrino, Giuseppe Fanciulli, Francesca Rota, Antongiulio Faggiano, Annamaria Colao, Manuela Albertelli, Vito Amoroso, Emanuela Arvat, Giuseppe Badalamenti, Emilio Bajetta, Roberto Baldelli, Antonio Bianchi, Roberto Buzzoni, Davide Campana, Carlo Carnaghi, Giacomo Cartenì, Sara Cingarlini, Vittorio Colantuoni, Jorgelina CoppaFrancesco Corcione, Maria Vittoria Davı´, Gaetano De Rosa, Ettore C. Degli Uberti, Marialaura Del Basso de Caro, Antonella Di Sarno, Massimo Falconi, Piero Ferolla, Diego Ferone, Germano Gaudenzi, Carla Giordano, Dario Giuffrida, Erika Maria Grossrubatscher, Elia Guadagno, Valentina Guarnotta, Andrea Lania, Silvana Leo, Fabio Lo Calzo, Francesco Logoluso, Marco Manzoni, Massimo Marchetti, Chiara Martini, Erika Messina, Massimo Milione, On Behalf Of Nike Group

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods: With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results: We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four widespread international guidelines. Conclusions: Our critical review confirms the lack of high-quality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.

Original languageEnglish
Pages (from-to)1-16
Number of pages16
JournalJournal of Cancer Research and Clinical Oncology
DOIs
Publication statusPublished - Jul 2017

Fingerprint

Neuroendocrine Tumors
Clinical Trials
Prospective Studies
Guidelines
Therapeutics
Registries
Retrospective Studies
Everolimus
Databases
Insulin
Growth
Neoplasms

Keywords

  • Everolimus
  • mTOR inhibitors
  • Neuroendocrine tumours
  • Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Everolimus as first line therapy for pancreatic neuroendocrine tumours : current knowledge and future perspectives. / Gallo, Marco; Malandrino, Pasqualino; Fanciulli, Giuseppe; Rota, Francesca; Faggiano, Antongiulio; Colao, Annamaria; Albertelli, Manuela; Amoroso, Vito; Arvat, Emanuela ; Badalamenti, Giuseppe; Bajetta, Emilio; Baldelli, Roberto; Bianchi, Antonio; Buzzoni, Roberto; Campana, Davide; Carnaghi, Carlo; Cartenì, Giacomo; Cingarlini, Sara; Colantuoni, Vittorio; Coppa, Jorgelina; Corcione, Francesco; Davı´, Maria Vittoria; De Rosa, Gaetano; Degli Uberti, Ettore C.; Del Basso de Caro, Marialaura; Di Sarno, Antonella; Falconi, Massimo; Ferolla, Piero; Ferone, Diego; Gaudenzi, Germano; Giordano, Carla; Giuffrida, Dario; Grossrubatscher, Erika Maria; Guadagno, Elia; Guarnotta, Valentina; Lania, Andrea; Leo, Silvana; Lo Calzo, Fabio; Logoluso, Francesco; Manzoni, Marco; Marchetti, Massimo; Martini, Chiara; Messina, Erika; Milione, Massimo; On Behalf Of Nike Group.

In: Journal of Cancer Research and Clinical Oncology, 07.2017, p. 1-16.

Research output: Contribution to journalArticle

Gallo, M, Malandrino, P, Fanciulli, G, Rota, F, Faggiano, A, Colao, A, Albertelli, M, Amoroso, V, Arvat, E, Badalamenti, G, Bajetta, E, Baldelli, R, Bianchi, A, Buzzoni, R, Campana, D, Carnaghi, C, Cartenì, G, Cingarlini, S, Colantuoni, V, Coppa, J, Corcione, F, Davı´, MV, De Rosa, G, Degli Uberti, EC, Del Basso de Caro, M, Di Sarno, A, Falconi, M, Ferolla, P, Ferone, D, Gaudenzi, G, Giordano, C, Giuffrida, D, Grossrubatscher, EM, Guadagno, E, Guarnotta, V, Lania, A, Leo, S, Lo Calzo, F, Logoluso, F, Manzoni, M, Marchetti, M, Martini, C, Messina, E, Milione, M & On Behalf Of Nike Group 2017, 'Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives', Journal of Cancer Research and Clinical Oncology, pp. 1-16. https://doi.org/10.1007/s00432-017-2407-5
Gallo, Marco ; Malandrino, Pasqualino ; Fanciulli, Giuseppe ; Rota, Francesca ; Faggiano, Antongiulio ; Colao, Annamaria ; Albertelli, Manuela ; Amoroso, Vito ; Arvat, Emanuela ; Badalamenti, Giuseppe ; Bajetta, Emilio ; Baldelli, Roberto ; Bianchi, Antonio ; Buzzoni, Roberto ; Campana, Davide ; Carnaghi, Carlo ; Cartenì, Giacomo ; Cingarlini, Sara ; Colantuoni, Vittorio ; Coppa, Jorgelina ; Corcione, Francesco ; Davı´, Maria Vittoria ; De Rosa, Gaetano ; Degli Uberti, Ettore C. ; Del Basso de Caro, Marialaura ; Di Sarno, Antonella ; Falconi, Massimo ; Ferolla, Piero ; Ferone, Diego ; Gaudenzi, Germano ; Giordano, Carla ; Giuffrida, Dario ; Grossrubatscher, Erika Maria ; Guadagno, Elia ; Guarnotta, Valentina ; Lania, Andrea ; Leo, Silvana ; Lo Calzo, Fabio ; Logoluso, Francesco ; Manzoni, Marco ; Marchetti, Massimo ; Martini, Chiara ; Messina, Erika ; Milione, Massimo ; On Behalf Of Nike Group. / Everolimus as first line therapy for pancreatic neuroendocrine tumours : current knowledge and future perspectives. In: Journal of Cancer Research and Clinical Oncology. 2017 ; pp. 1-16.
@article{d3d4149eba9247f3b66c734b3b19f582,
title = "Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives",
abstract = "Purpose: Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods: With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results: We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four widespread international guidelines. Conclusions: Our critical review confirms the lack of high-quality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.",
keywords = "Everolimus, mTOR inhibitors, Neuroendocrine tumours, Therapy",
author = "Marco Gallo and Pasqualino Malandrino and Giuseppe Fanciulli and Francesca Rota and Antongiulio Faggiano and Annamaria Colao and Manuela Albertelli and Vito Amoroso and Emanuela Arvat and Giuseppe Badalamenti and Emilio Bajetta and Roberto Baldelli and Antonio Bianchi and Roberto Buzzoni and Davide Campana and Carlo Carnaghi and Giacomo Carten{\`i} and Sara Cingarlini and Vittorio Colantuoni and Jorgelina Coppa and Francesco Corcione and Davı´, {Maria Vittoria} and {De Rosa}, Gaetano and {Degli Uberti}, {Ettore C.} and {Del Basso de Caro}, Marialaura and {Di Sarno}, Antonella and Massimo Falconi and Piero Ferolla and Diego Ferone and Germano Gaudenzi and Carla Giordano and Dario Giuffrida and Grossrubatscher, {Erika Maria} and Elia Guadagno and Valentina Guarnotta and Andrea Lania and Silvana Leo and {Lo Calzo}, Fabio and Francesco Logoluso and Marco Manzoni and Massimo Marchetti and Chiara Martini and Erika Messina and Massimo Milione and {On Behalf Of Nike Group}",
year = "2017",
month = "7",
doi = "10.1007/s00432-017-2407-5",
language = "English",
pages = "1--16",
journal = "Journal of Cancer Research and Clinical Oncology",
issn = "0171-5216",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Everolimus as first line therapy for pancreatic neuroendocrine tumours

T2 - current knowledge and future perspectives

AU - Gallo, Marco

AU - Malandrino, Pasqualino

AU - Fanciulli, Giuseppe

AU - Rota, Francesca

AU - Faggiano, Antongiulio

AU - Colao, Annamaria

AU - Albertelli, Manuela

AU - Amoroso, Vito

AU - Arvat, Emanuela

AU - Badalamenti, Giuseppe

AU - Bajetta, Emilio

AU - Baldelli, Roberto

AU - Bianchi, Antonio

AU - Buzzoni, Roberto

AU - Campana, Davide

AU - Carnaghi, Carlo

AU - Cartenì, Giacomo

AU - Cingarlini, Sara

AU - Colantuoni, Vittorio

AU - Coppa, Jorgelina

AU - Corcione, Francesco

AU - Davı´, Maria Vittoria

AU - De Rosa, Gaetano

AU - Degli Uberti, Ettore C.

AU - Del Basso de Caro, Marialaura

AU - Di Sarno, Antonella

AU - Falconi, Massimo

AU - Ferolla, Piero

AU - Ferone, Diego

AU - Gaudenzi, Germano

AU - Giordano, Carla

AU - Giuffrida, Dario

AU - Grossrubatscher, Erika Maria

AU - Guadagno, Elia

AU - Guarnotta, Valentina

AU - Lania, Andrea

AU - Leo, Silvana

AU - Lo Calzo, Fabio

AU - Logoluso, Francesco

AU - Manzoni, Marco

AU - Marchetti, Massimo

AU - Martini, Chiara

AU - Messina, Erika

AU - Milione, Massimo

AU - On Behalf Of Nike Group

PY - 2017/7

Y1 - 2017/7

N2 - Purpose: Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods: With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results: We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four widespread international guidelines. Conclusions: Our critical review confirms the lack of high-quality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.

AB - Purpose: Everolimus has been shown to be effective for advanced pancreatic neuroendocrine tumours (pNETs), but its positioning in the therapeutic algorithm for pNETs is matter of debate. Methods: With the aim to shed light on this point, we performed an up-to-date critical review taking into account the results of both retrospective and prospective published studies, and the recommendations of international guidelines. In addition, we performed an extensive search on the Clinical Trial Registries databases worldwide, to gather information on the ongoing clinical trials related to this specific topic. Results: We identified eight retrospective published studies, two prospective published studies, and five registered clinical trials. Moreover, we analyzed the content of four widespread international guidelines. Conclusions: Our critical review confirms the lack of high-quality data to recommend everolimus as the first line therapy for pNETs. The ongoing clinical trials reported in this review will hopefully help clinicians, in the near future, to better evaluate the role of everolimus as the first line therapy for pNETs. However, at the moment, there is already enough evidence to recommend everolimus as the first line therapy for patients with symptomatic malignant unresectable insulin-secreting pNETs, to control the endocrine syndrome regardless of tumour growth.

KW - Everolimus

KW - mTOR inhibitors

KW - Neuroendocrine tumours

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=85017464796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017464796&partnerID=8YFLogxK

U2 - 10.1007/s00432-017-2407-5

DO - 10.1007/s00432-017-2407-5

M3 - Article

AN - SCOPUS:85017464796

SP - 1

EP - 16

JO - Journal of Cancer Research and Clinical Oncology

JF - Journal of Cancer Research and Clinical Oncology

SN - 0171-5216

ER -